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 The nonpurine selective xanthine oxidase (XO) inhibitor febuxostat attenuates development of
left ventricular (LV) hypertrophy and dysfunction in mice when treatment is initiated within 1 hour
of transverse aortic constriction (TAC). This study investigated whether a 7-day delay of treatment
with the XO inhibitors febuxostat or allopurinol would reverse TAC-induced changes after onset
of heart failure (HF). Neither treatment signiﬁcantly affected TAC-induced LV hypertrophy; only
febuxostat caused a modest improvement in LV function (∼10% increase in LV ejection fraction).
However, the purine analog allopurinol tended to increase mortality compared with vehicle or febux-
ostat in HF mice.
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INTRODUCTION
Inhibitionofxanthineoxidase(XO)withthepurineanalogsallopurinol
or oxypurinol has been reported to improve left ventricular (LV) function
in the failing human heart or in animal models with failing hearts[1–3] and
to protect the heart against LV remodeling in animals after myocardial
infarction.[4–6] We have reported that XO inhibition with the nonpurine se-
lective XO inhibitorfebuxostat (5 mg/kg p.o. for 8 days), given ∼60 minutes
after transverse aortic constriction (TAC) in mice, can signiﬁcantly attenu-
ate systolic overload-induced LV hypertrophy, dysfunction, and ﬁbrosis.[7]
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The cardiac protective effect was associated with reduced oxidative stress
as measured by myocardial nitrotyrosine levels. Moreover, febuxostat also
attenuated the TAC-induced phosphorylation of the mammalian target of
rapamycin (mTOR) and extracellular signal-regulated kinase (Erk), events
that are thought to mediate myocardial hypertrophy.
The purpose of this study was to investigate whether delayed XO inhi-
bition with febuxostat (0.05 mg/ml in drinking water, ∼5 mg/kg/day) or
allopurinol (0.15 mg/ml in drinking water, ∼15 mg/kg/day) could reverse
TAC-induced changes at a time when heart failure (HF) was already estab-
lished (7 days after TAC) using the mouse model described previously.[7]
Mortalityratewasrecordedduringthe3-weektreatmentperiod.Echocardio-
graphy was performed to measure LV function and dimensions. Myocardial
ﬁbrosis and cardiac myocyte sizes were measured by histological staining.
MATERIALS AND METHODS
Minimally Invasive TAC Procedure
Male C57/BL6 mice 8–9 weeks of age (body weight 20–25 g) were used
in the study. TAC was performed using the minimally invasive suprasternal
approach as previously described,[7] except that a 26-G needle was used with
ligation of the aorta.
Experimental Protocol
Mice subjected to TAC or sham surgery were divided into 6 experimen-
tal groups. Beginning 7 days after surgery, TAC- and sham-operated ani-
mals were given access to drinking water treated with vehicle (0.01 mg/ml
NaCl, salt content equivalent to that in the febuxostat drinking water),
febuxostat (0.05 mg/ml, ∼5 mg/kg/day), or allopurinol (0.15 mg/ml, ∼15
mg/kg/day). Following 3 weeks of treatment, ventricular function was as-
sessed by echocardiography. Blood samples and cardiac tissues were col-
lected 2–3 hours after echocardiographic evaluation for determination of
plasma uric acid (UA) levels and histological staining. The wet weights of
the ventricle and lung of each animal were also measured with an electric
balance and normalized as the ratio of organ weight to body weight.
Echocardiography
Echocardiographywasperformedonmiceanesthetizedwith1.5%isoﬂu-
rane by inhalation as we previously described.[7–9]308 X. Xu et al.
Histological Staining and Measurement of Cardiac
Myocyte Hypertrophy
Tissue sections of the central portion of the LV were stained with Mas-
son’s trichrome for detection of myocardial ﬁbrosis as we previously de-
scribed.[9] Fluorescein isothiocyanate (FITC)-conjugated wheat germ agglu-
tinin was used to stain the cell membrane for determination of cardiac
myocyte size.[8,9]
Plasma UA Analysis
The concentration of UA in plasma was determined using UA reagent
(ThermoDMA, Louisville, CO, USA) according to the manufacturer’s
protocol.
Data and Statistical Analyses
All values are expressed as mean ± standard error of the mean (SEM).
One-way analysis of variance (ANOVA) was used to test each variable for
differences among the treatment groups. Statistical signiﬁcance was deﬁned
as P < 0.05. If the ANOVA indicated a signiﬁcant effect, post hoc pairwise
comparisonsweremadeusingtheFisherleastsigniﬁcantdifferencetest.The
Fisher exact test was used to compare mortality data among the treatment
groups.
RESULTS
Effects of XO Inhibition on Plasma UA Levels
As expected, both febuxostat and allopurinol signiﬁcantly decreased
plasma UA in the sham-operated groups (Figure 1). TAC tended to increase
plasma UA levels relative to the sham-operated controls, and both XO in-
hibitors decreased plasma UA in TAC animals to a similar extent, although
these changes did not reach statistical signiﬁcance due to large variability
between animals. Nevertheless, these data suggest that febuxostat and allo-
purinol were given at similar XO inhibitory doses.
Effects of XO Inhibition on TAC-Induced Mortality Rate
Mortality was low over the 3-week treatment period in TAC mice treated
with vehicle (2 of 26 mice died, 8% mortality) or febuxostat (1 of 28 mice
died, 4% mortality). However, the mortality in TAC animals treated with
allopurinol was 24% (4 of 17 died, P = 0.19 vs. vehicle control and P = 0.06
vs. febuxostat group; Figure 2).Febuxostat and Allopurinol in Heart Failure Mice 309
FIGURE 1 Effect of 3-week febuxostat (FBS) or allopurinol (AL) treatment on plasma UA. Treatment
was started 7 days following sham or TAC procedures and continued for 3 weeks. ∗p < 0.05 as compared
with the corresponding sham group. VH = vehicle. TAC = transverse aortic constriction.
Effects of XO Inhibition on TAC-Induced LV Hypertrophy
and Dysfunction
Febuxostat and allopurinol had no signiﬁcant effects on ratios of ven-
tricular and lung weights normalized to body weights in the sham groups.
Chronic TAC resulted in a signiﬁcant increase in body weight-normalized
ventricular weight and tended to increase normalized lung weight; nei-
ther agent had a signiﬁcant effect on these changes compared with vehicle
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FIGURE 2 Effect of febuxostat (FBS) or allopurinol (AL) on the survival of mice during 3 weeks of
treatment beginning 7 days following sham or TAC procedures. VH = vehicle. TAC = transverse aortic
constriction.310 X. Xu et al.
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FIGURE 3 Effects of 3-week febuxostat (FBS) or allopurinol (AL) treatment on ratios of ventricle/body
and lung/body weights. Treatment was started 7 days following sham or TAC procedures and continued
for3weeks. ∗p <0.05ascomparedwiththecorrespondingshamcontrol.VH=vehicle.TAC=transverse
aortic constriction.
(Figure 3). These results suggest that, unlike what occurs with early treat-
ment, a delay in XO inhibition until after the onset of cardiac hypertrophy
and HF has no effect on TAC-induced ventricular hypertrophy.
TheeffectsoffebuxostatandallopurinolonLVfunctionanddimensions
measured by echocardiography are presented in Figure 4. In sham-operated
animals,febuxostatresultedinasmallincreaseinLVejectionfraction(∼9%,
Figure 4A) and fractional shortening (∼15%, data not shown). Although
febuxostat had no effect on TAC-induced ventricular hypertrophy, it did
induce a small, but statistically signiﬁcant, improvement in the LV ejection
fraction (∼10% increase) and LV fractional shortening (∼16%, data not
shown) compared with vehicle-treated TAC animals (Figure 4A). Febuxo-
stat also tended to attenuate the TAC-induced increase in LV end-systolic
diameter, which correlates with the ﬁnding of improved fractional shorten-
ing (Figure 4C). In contrast, allopurinol had no effect on LV function or
dimensions (Figure 4) in either sham or TAC mice.
Histological staining indicated that TAC resulted in signiﬁcant ventricu-
lar ﬁbrosis and increases in myocyte diameter (indicating cardiac hypertro-
phy). These changes were not affected by either febuxostat or allopurinol
(data not shown), which is consistent with the results on ventricular dimen-
sions as measured by echocardiography.
DISCUSSION
In our previous study, an 8 day-treatment of febuxostat beginning ap-
proximately 60 minutes after TAC signiﬁcantly attenuated the TAC-induced
ventricular hypertrophy, dilation, ﬁbrosis, and dysfunction.[7] FebuxostatFebuxostat and Allopurinol in Heart Failure Mice 311
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FIGURE 4 Effects of 3-week febuxostat (FBS) or allopurinol (AL) treatment on LV function and dimen-
sions. Data are for LV ejection fraction (A), LV end-systolic wall thickness (B), LV end-systolic diameter
(C), and LV end-diastolic diameter (D). Treatment was started 7 days following sham or TAC procedures
and continued for 3 weeks. ∗p < 0.05 as compared with the corresponding sham group. # p < 0.05 as
compare with the corresponding vehicle group. LV = left ventricular. VH = vehicle. TAC = transverse
aortic constriction.
also signiﬁcantly attenuated the TAC-induced phosphorylation of mTOR
and Erk, and the increase of myocardial atrial natriuretic peptide. In the
present study, the effects of febuxostat treatment were diminished when
treatment was initiated 7 days after TAC. Delayed treatment with febuxostat
hadnoeffectonLVhypertrophyandcausedonlymodestimprovementinLV
function. Keeping in mind the limitations of experimental data from mice, a
species in which uric acid is not the ﬁnal product of purine catabolism, these
results suggest that XO inhibition by febuxostat could be an effective thera-
peutic approach for the prevention of cardiac hypertrophy and dysfunction
induced by systolic overload,[7] but it may not be an effective treatment once
HF has been established. These results are in agreement with ﬁndings from
a study[10] using a rabbit myocardial infarction model, in which 7 weeks of
daily oral administration of febuxostat, starting a day after coronary artery
ligation, signiﬁcantly lessened the reduction in LV function. As in the cur-
rent study, however, these effects were not seen if the initiation of treatment
with febuxostat or allopurinol was delayed until after the onset of HF.[10]312 X. Xu et al.
In the present study using the TAC mouse model, treatment with allo-
purinol had no beneﬁcial, and perhaps even a deleterious, effect as a treat-
ment for established HF. Although administration of allopurinol resulted
in a decrease in plasma UA levels that was similar to that of febuxostat, al-
lopurinol treatment produced no improvement in either LV hypertrophy
or function. Moreover, allopurinol treatment tended to increase mortality
(24%) compared with vehicle (8%) or febuxostat (4%) treatment of mice
with TAC.
Whether there is a true difference in the mortality rates between the
TAC animals treated with allopurinol compared with febuxostat or vehicle
requires further conﬁrmative investigation. Different biological effects be-
tween these two agents are not unexpected because of differences in their
chemical structures, selectivity, and mode of XO inhibition.[11,12] Febuxo-
stat is different from allopurinol in that it is a nonpurine molecule and
does not inhibit other enzymes in purine and pyrimidine metabolism path-
ways.[11] Moreover, unlike allopurinol, which is a substrate of XO (suicide
XO inhibitor) and a prodrug for the active metabolite oxypurinol, febux-
ostat directly inhibits XO simply by obstructing substrate binding and this
inhibition is not inﬂuenced by the redox status of the cofactor.[12]
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